CYTH vs. IVVD, TVGN, CMPX, XFOR, AGEN, OPT, VXRT, ATHA, BLUE, and ATYR
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include Invivyd (IVVD), Tevogen Bio (TVGN), Compass Therapeutics (CMPX), X4 Pharmaceuticals (XFOR), Agenus (AGEN), Opthea (OPT), Vaxart (VXRT), Athira Pharma (ATHA), bluebird bio (BLUE), and Atyr PHARMA (ATYR). These companies are all part of the "biological products, except diagnostic" industry.
Cyclo Therapeutics (NASDAQ:CYTH) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
Invivyd has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -1,720.76%. Invivyd's return on equity of -93.58% beat Cyclo Therapeutics' return on equity.
In the previous week, Invivyd had 1 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 3 mentions for Invivyd and 2 mentions for Cyclo Therapeutics. Invivyd's average media sentiment score of 0.49 beat Cyclo Therapeutics' score of 0.43 indicating that Invivyd is being referred to more favorably in the news media.
Cyclo Therapeutics presently has a consensus target price of $3.20, suggesting a potential upside of 178.26%. Invivyd has a consensus target price of $11.33, suggesting a potential upside of 758.59%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Cyclo Therapeutics.
Cyclo Therapeutics has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
Cyclo Therapeutics and Invivyd both received 8 outperform votes by MarketBeat users. However, 80.00% of users gave Cyclo Therapeutics an outperform vote while only 66.67% of users gave Invivyd an outperform vote.
Cyclo Therapeutics has higher revenue and earnings than Invivyd. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.
68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by company insiders. Comparatively, 17.9% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Invivyd beats Cyclo Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
